Samsung Bioepis Pushes On With Pembrolizumab Phase III, Even As Others Terminate Trials

Despite Streamlining Momentum, Korean Firm Sees Value In Trial Data

 
• By Dave Wallace
  
Samsung Bioepis is moving ahead with a Phase III trial for pembrolizumab while others are stopping (Shutterstock)

More from Strategy

More from Business